MarketPeel
Insider Trading Intelligence
AD

Allison Dorval

PBYI
DIRECTOR · PUMA BIOTECHNOLOGY, INC. · CIK 0001625110
FILING MIX · LIFETIME61%/39%
BUYS
11
SELLS
7
TOTAL VALUE
$285.9K
COMPANIES
2
ACTIVE SINCE
Jan 2020
HOLDINGS NOW
200,674
AVG SELL PX
$5.35
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
5 backtested trades · 8 horizons · 1 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Allison Dorval, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d5+80.00%-5.17%-0.10%-5.07%-4.02%
14d5+80.00%-2.89%+0.99%-3.88%-3.76%
30d5+60.00%-2.09%+3.28%-5.37%-4.19%
60d5+40.00%-4.49%-3.56%-0.94%+5.74%
90d5+80.00%-12.51%+2.06%-14.57%-7.63%
180d5+60.00%+1.43%+9.72%-8.30%-1.60%
1y5+40.00%+2.95%+21.11%-18.16%-23.35%
2y5(1 pending)+25.00%+10.97%+31.48%-20.51%-20.82%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
PBYI · 90,780 shares · as of Jun 12, 2026
027,18054,36181,541108,72120222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 11 buys / 7 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
11,610$7.20$83.6K90,780Jun 12, 2026Jun 15, 2026View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,000102,390Jun 11, 2026Jun 15, 2026View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
11,610$3.40$39.5K75,390Jun 13, 2025Jun 17, 2025View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00087,000Jun 11, 2025Jun 13, 2025View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00060,000Jun 18, 2024Jun 21, 2024View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
11,000$3.37$37.1K33,000Jun 13, 2024Jun 17, 2024View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00044,000Jun 13, 2023Jun 15, 2023View →
PBYI
PUMA BIOTECHNOLOGY, INC.
SALE10b5-1
10b5-1 plan
10,000$3.45$34.5K17,000Jun 13, 2023Jun 15, 2023View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
27,00027,000Jun 14, 2022Jun 16, 2022View →
PBYI
PUMA BIOTECHNOLOGY, INC.
PURCHASEGRANT
Stock grant
108,721108,721Jul 15, 2021Jul 16, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
30,000109,894Mar 19, 2021Mar 23, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
34,00079,894Feb 16, 2021Feb 18, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
68,00068,000Feb 16, 2021Feb 18, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,186$7.55$24.1K45,894Feb 11, 2021Feb 16, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
Chief Financial Officer
2,942$8.62$25.4K49,080Jan 12, 2021Jan 14, 2021View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
55,00055,000Feb 10, 2020Feb 12, 2020View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
27,50052,022Feb 10, 2020Feb 12, 2020View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
Chief Financial Officer
3,128$13.36$41.8K24,522Jan 21, 2020Jan 29, 2020View →
Other insiders · PBYI
Loading peer insiders…
About this filer
CIK 0001625110
ROLE
Director
PRIMARY
PBYI
COMPANIES
2
ACTIVE SINCE
Jan 2020
MARKETPEEL · /INSIDER/0001625110DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback